Curology has announced it has secured $15 million in Series B funding, which will help the brand scale. The financing is led by Advance Vixeid Partners, with participation from prior investors Sherpa Capital and Forerunner Ventures.

Curology is a customized, prescription-only skin care line that is sold directly to consumers through a subscription service. It was founded in 2014 by dermatologist David Lortscher, MD.

Lortscher said, “This funding will accelerate Curology’s mission to provide effective and affordable acne and anti-aging treatments to people across the country. Our business has grown 5x in the past year; the capital raised will allow us to serve even more consumers frustrated by the skincare options available in the market today.”

Take a look at the customized label on the bottle above, for a personalized formulation. Photo by GeekyPosh. 

How It Works

Curology offers acne and aging-related dermatology consultations at lower costs than in-person visits – plus, customized prescriptions. Consumers share photos of their skin, and a licensed medical professional uses the Company’s platform to evaluate their condition and prescribe a personalized topical solution.

The product is sent directly to the customer on a recurring basis, and the formula is adjusted as necessary through an ongoing relationship with Curology’s medical professionals.

Lortscher explains, “In the US, there is only one dermatologist for every 36,000 people – and most are concentrated in major metro areas, meaning access to specialists is limited. As a result, many consumers settle for inadequate over-the-counter remedies. With Curology, they get one-on-one dermatology care and personalized, prescription strength treatment for just $20 per month.”

Courtney Robinson, Principal at Advance Vixeid Partners, added, “David and the Curology team are fundamentally transforming the multi-billion-dollar acne treatment market. By using technology to remove friction and cost from the conventional model, Curology can scale quickly and better serve consumers with accessible, effective, affordable treatment.”